Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 Second-Line Monotherapy in Advanced Biliary Tract Cancer
ChiCTR2600127873Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on ChiCTR2600127873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127873.